相似文献
1
Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.
J Hepatol. 2017 May;66(5):1101-1103. doi: 10.1016/j.jhep.2016.12.028. Epub 2017 Feb 3.
2
Reply to: "Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C".
J Hepatol. 2017 May;66(5):1103. doi: 10.1016/j.jhep.2017.01.021. Epub 2017 Feb 3.
3
Hepatitis C virus treatment as prevention in people who inject drugs.
Lancet Infect Dis. 2018 Apr;18(4):379. doi: 10.1016/S1473-3099(18)30130-0. Epub 2018 Mar 21.
4
Time to end treatment restrictions for people with hepatitis C who inject drugs.
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):142-143. doi: 10.1016/S2468-1253(18)30001-3. Epub 2018 Jan 6.
5
Prioritising treatment among people who inject drugs in order to eliminate hepatitis C: addressing reluctance with sound economic analyses.
Gut. 2017 Dec;66(12):2052-2053. doi: 10.1136/gutjnl-2016-312636. Epub 2016 Aug 26.
6
How to eliminate HCV in people who inject drugs in the USA.
Lancet Infect Dis. 2018 Feb;18(2):134-135. doi: 10.1016/S1473-3099(17)30678-3. Epub 2017 Nov 15.
7
The changing landscape of hepatitis C treatment-not 'can we cure?' but 'who should we cure first?' Is this an ethical approach?
Addiction. 2015 Jun;110(6):984-5. doi: 10.1111/add.12912.
8
Hepatitis C virus infection in people who inject drugs in Africa.
Lancet Infect Dis. 2020 Mar;20(3):283-284. doi: 10.1016/S1473-3099(20)30051-7.
9
Hepatitis C virus infection in people who inject drugs in Africa.
Lancet Infect Dis. 2020 Mar;20(3):282-283. doi: 10.1016/S1473-3099(20)30049-9.
10
Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs.
Int J Drug Policy. 2015 Nov;26(11):1039-40. doi: 10.1016/j.drugpo.2015.07.008. Epub 2015 Jul 17.
引用本文的文献
1
Practical steps to improve chronic hepatitis C treatment in people with opioid use disorder.
Hepat Med. 2018 Dec 24;11:1-11. doi: 10.2147/HMER.S187133. eCollection 2019.
2
Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.
Int J Drug Policy. 2018 Jul;57:51-60. doi: 10.1016/j.drugpo.2018.03.023. Epub 2018 Apr 19.
本文引用的文献
1
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
Clin Infect Dis. 2016 Dec 1;63(11):1479-1481. doi: 10.1093/cid/ciw579. Epub 2016 Aug 23.
2
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Clin Infect Dis. 2016 Dec 1;63(11):1405-1411. doi: 10.1093/cid/ciw580. Epub 2016 Aug 23.
3
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Ann Intern Med. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9.
4
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
Ann Intern Med. 2015 Jul 7;163(1):1-13. doi: 10.7326/M15-0785.
5
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
J Hepatol. 2015 Aug;63(2):364-9. doi: 10.1016/j.jhep.2015.03.029. Epub 2015 Apr 1.
6
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
N Engl J Med. 2014 Apr 24;370(17):1594-603. doi: 10.1056/NEJMoa1315722. Epub 2014 Apr 10.
Zotero 插件